DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $441,970 | +10.6% | 1,781 | +7.0% | 0.05% | +15.6% |
Q2 2023 | $399,461 | -12.6% | 1,664 | -8.3% | 0.04% | -33.8% |
Q1 2023 | $457,201 | -29.2% | 1,814 | -25.5% | 0.07% | -33.3% |
Q4 2022 | $646,032 | +55.7% | 2,434 | +51.5% | 0.10% | +6.2% |
Q3 2022 | $415,000 | +52.0% | 1,607 | +49.3% | 0.10% | +35.2% |
Q2 2022 | $273,000 | -54.3% | 1,076 | -47.2% | 0.07% | -45.0% |
Q1 2022 | $598,000 | -14.8% | 2,038 | -4.5% | 0.13% | -14.6% |
Q4 2021 | $702,000 | -36.9% | 2,134 | -41.6% | 0.15% | -32.0% |
Q3 2021 | $1,112,000 | +10.0% | 3,652 | -3.1% | 0.22% | -4.7% |
Q2 2021 | $1,011,000 | +27.3% | 3,768 | +6.8% | 0.23% | +9.4% |
Q1 2021 | $794,000 | +4.3% | 3,528 | +3.0% | 0.21% | -13.1% |
Q4 2020 | $761,000 | +7.6% | 3,426 | +4.4% | 0.24% | -12.2% |
Q3 2020 | $707,000 | +36.0% | 3,282 | +11.7% | 0.28% | +15.3% |
Q2 2020 | $520,000 | +27.8% | 2,938 | 0.0% | 0.24% | +7.1% |
Q1 2020 | $407,000 | -21.3% | 2,938 | -12.8% | 0.23% | -8.5% |
Q4 2019 | $517,000 | – | 3,369 | – | 0.25% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |